- Electronics, IT and Telecomms
- Industrial manufacturing, Material and Transport Technologies
- Industrial Technologies
- Energy Technology
- Physical Sciences and Exact Sciences
- Biological Sciences
- Agriculture and Marine Resources
- Agrofood Industry
- Measurements and Standards
- Protecting Man and Environment
- Social and Economics concerns
- Communications
- Computer related
- Electronics Related Market
- Genetic Engineering / Molecular Biology
- Medical Health related
- Energy Market
- Consumer related
- Industrial Products
- Other
Innoget posted this Technology Call
Seeking innovative proposals in the AI domain to boost the productivity and competitiveness of EU industriesArtificial Intelligence is a rapidly developing technology with the potential to influence or transform almost every aspect of the economy and society. In-depth knowledge and leadership in developing and applying this powerful capability is an essential requirement, if industry is to maintain its leadership in multiple application areas, or take advantage of new opportunities. This EUREKA Clusters AI Call is specifically designed to stimulate activity in this important area, through the creation of trans-national collaborative projects in applications that will support economic growth and benefit society as a whole. Participants are invited to submit applied research and innovation project proposals in the field of Artificial intelligence, indicating, where possible, how they are related to the technological focus area of the participating Clusters most relevant to their proposal.
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this Technology Call
Seeking candidates to apply to the LifeArc COVID-19 FundLifeArc has made available an initial £10M for the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. It is anticipated that applications will be for funding to repurpose one or more drugs that are generic, already licensed, or are in late stage development for another indication.
